CRRT in vitro low-temperature coagulation resisting system and blood purifying method

Abstract

The invention belongs to the technical field of medical care, and particularly relates to a CRRT in vitro low-temperature coagulation resisting system and a blood purifying method using the low-temperature coagulation resisting system. The CRRT in vitro low-temperature coagulation resisting system comprises a CRRT blood purifying instrument (1), a controller (2), a cooling control unit (3), a warming control unit (4) and a pipeline (10), wherein before blood enters the blood purifying instrument (1), the blood is cooled by the cooling control unit (3) to realize low-temperature coagulation resisting action; and the blood is purified by the blood purifying instrument (1) to be input to human bodies, and blood temperature is increased by the warming control unit (4) to body temperature of human bodies. A physical manner is adopted to realize blood coagulation resistance, so that the CRRT in vitro low-temperature coagulation resisting system has the advantages of being small in side effects, convenient to operate, long in coagulation resisting time and the like.

Description

technical field [0001] The invention belongs to the field of medical technology, in particular to a CRRT extracorporeal low temperature anticoagulation system. Background technique [0002] In recent years, blood purification technology has been widely used clinically in the rescue treatment of various critically ill patients, and it is one of the important means of organ support. Blood purification is to lead the patient's blood out of the body and pass through a purification device to remove some pathogenic substances in it, so as to purify the blood and achieve the purpose of treating diseases. Since Kramer et al. first proposed continuous arteriovenous hemofiltration (CAVH) in 1977 and applied it clinically, with the continuous development of technology, after more than 20 years of clinical practice, people collectively refer to a series of treatment modes derived from CAVH as continuous Continuous renal replacement therapy (CRRT), currently refers to a variety of treat...

AI Technical Summary

Problems solved by technology

In our previous research, we found that when normal plasma standards were tested under different temperature conditions (37°C, 35°C, 32°C, 30°C, 28°C), the average prothrombin time and partially activated prothrombin time were both is prolonged with decreasing temperature; demonstrates that low temperature inhibits the coagulation cascade in the presence of normal levels of inhibitory coagulation factors, leading to coagulation dysfunction

Images